Baird Medical Investment Holdings Ltd. filings document foreign-issuer current reports for a microwave ablation medical device company. The disclosed records include Form 6-K reporting on auditor changes, board and audit committee actions, and financial-reporting controls.
The company's SEC disclosures also address accounting and reporting matters relevant to its Form 20-F status, including U.S. GAAP and SEC reporting requirements, independent registered public accounting firm appointments, and disclosed material weaknesses in internal control over financial reporting.
ExcelFin SPAC LLC, a ten percent owner of Baird Medical Investment Holdings Ltd, reported its initial holdings of ordinary shares. The disclosure explains that Fin Venture Capital Management, LLC holds 12.5% and Grand Fortune Capital, LLC holds 87.5% of ExcelFin’s membership interests, with related entities GFCHK and GFC also holding ordinary shares. ExcelFin, FVC and GFC disclaim beneficial ownership of the reported shares except to the extent of any pecuniary interest, and actions regarding ExcelFin’s shares require a majority vote of GFCHK’s three-member board of managers.
Baird Medical Investment Holdings Ltd’s ordinary shares are the subject of a Schedule 13D filed by ExcelFin SPAC LLC, Grand Fortune Capital (HK) Company Limited, and Grand Fortune Capital LLC following a business combination involving the issuer.
Based on 36,725,899 ordinary shares outstanding as of January 15, 2026, ExcelFin beneficially owns 4,249,031 shares (11.6%). Grand Fortune Capital LLC beneficially owns 290,000 shares on an as-converted basis from Series A Preferred Shares (0.8%). Grand Fortune Capital (HK) Company Limited is deemed to beneficially own 7,004,016 shares (19.1%), including ExcelFin’s holdings and the convertible preferred position of Grand Fortune Capital LLC. The securities were obtained through the business combination, conversion of working capital loans at $10.20 per share, and a $2.9 million preferred share subscription. The reporting persons state they hold the position for investment purposes and may acquire or dispose of BDMD securities or discuss strategy, governance, and potential transactions with the company.
Baird Medical Investment Holdings Limited, a thyroid-focused microwave ablation device company, reports a sharp reversal in 2025 results. Revenue fell 39.2% to US$22.5 million from US$37.0 million in 2024, and net income of US$12.6 million in 2024 turned into a net loss of US$27.5 million in 2025. Sales remain concentrated in the PRC, though 2025 included contributions from Hong Kong, the United States, Malaysia and Nepal.
The revenue decline stemmed mainly from slower purchasing and more conservative approval procedures at China hospitals amid an anti-corruption campaign, especially affecting direct sales, while distributor revenue rose modestly. Despite lower volume, gross margin stayed high at 83.8%. The loss was driven by a surge in operating expenses to US$44.5 million, including US$17.5 million of share-based compensation and research and development expenses of US$20.1 million tied to FDA and CE work and AI ablation systems.
Liquidity is tight: cash and restricted cash declined to US$0.6 million at December 31, 2025, though working capital was US$22.6 million. Net accounts receivable were US$42.5 million, equal to 188.9% of 2025 revenue, with 777 days of receivable turnover and most balances overdue. About US$5.8 million was collected through May 29, 2026, and management expects substantial additional collections during 2026–2027. The company renewed and added bank facilities at interest rates around 2.70%–2.71% and obtained a US$2.0 million support commitment and non-demand related-party payables. It also secured device registrations in multiple countries and, based on these factors, management concluded there was no substantial doubt about its ability to continue as a going concern for one year from the financial statement issuance date.
Baird Medical Investment Holdings Limited filed a post-effective amendment converting its Form F-1 into a Form F-3 and updated financials and disclosures. The amendment does not register additional securities and enables resale and future issuance under a shelf-style prospectus dated May 22, 2026. The prospectus registers up to 11,500,000 Ordinary Shares issuable upon exercise of warrants at $11.50 per share and up to 34,415,562 Ordinary Shares for resale by selling securityholders. The filing states the company will not receive proceeds from resale by selling securityholders and is unlikely to receive proceeds from warrant exercises at the May 21, 2026 closing price of $1.64 per share. The prospectus highlights China-related regulatory, cash‑transfer and HFCAA/PCAOB inspection risks and summarizes business focus, recent revenues and net income/(loss) for 2023–2025.
Baird Medical Investment Holdings Limited filed a Form F-3 shelf prospectus to offer up to US$50,000,000 of ordinary shares, preferred shares, debt securities, warrants and units, to be sold from time to time. The prospectus states offers may be at fixed, market or negotiated prices, through underwriters, agents or direct sales.
The company discloses revenue of $31.5M (2023), $37.0M (2024) and $22.5M (2025), net income of $10.7M (2023), $12.6M (2024) and a net loss of $27.5M (2025). Ordinary Shares outstanding were 42,208,763 and 290,000 Series A Preferred Shares issued. The prospectus highlights China-specific regulatory risks including HFCAA, CSRC filing requirements and cash-transfer restrictions.
Baird Medical Investment Holdings Ltd filing reports that Alta Partners LLC beneficially owns 1,995,604 shares of common stock, representing common stock issuable upon exercise of outstanding warrants. The position represents 5.1% of the class. The filing states the holdings were not acquired to change or influence control.
Baird Medical Investment Holdings Limited filed its annual Form 20-F as a Cayman Islands holding company whose operations are conducted through PRC subsidiaries. The report highlights that dividends and cash movements depend heavily on these subsidiaries and are subject to PRC foreign exchange and reserve restrictions.
The company details extensive PRC regulatory licensing for its Class III microwave ablation equipment and needles and a Class II biopsy needle, plus a Manufacture License for Class II and III medical devices valid to May 24, 2026. It discusses reliance on a concentrated distributor and customer base, third-party suppliers, and marketing service providers.
Key risks include evolving PRC healthcare regulation, the Holding Foreign Companies Accountable Act and possible Nasdaq delisting if PCAOB access is lost, prior compliance issues such as a lapsed manufacturing license and underpaid social insurance, dependence on tender processes and medical insurance reimbursement, and challenges in product development, clinical trials, and competition.
Baird Medical Investment Holdings Ltd director Xu Lijian filed an initial statement of beneficial ownership. The filing reports direct ownership of 25,000 RSU Shares (BDMD), indicating Xu’s equity position in the company through restricted stock unit shares.
Baird Medical Investment Holdings Ltd director Qiu Quan has filed an initial Form 3, formally registering as a reporting person for BDMD. The structured data shows no reported purchases, sales, or other transactions and no derivative positions in this initial ownership statement.
Baird Medical Investment Holdings Ltd submitted a Form 3 identifying Lu Rongjian as an officer of the company with the title Chief Technical Officer. The structured data shows no reported share transactions, derivative positions, or holding entries associated with this reporting person in this filing.